http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20190355-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50 |
| filingDate | 2017-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690cf824ad030eb757f4f434066c3408 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12c54f89113c02caa01188c3e7cb0d39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0402ff2ff2eec7d8efe81ef156e14c |
| publicationDate | 2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20190355-A1 |
| titleOfInvention | DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION INCLUDING THE SAME AND THERAPEUTIC USE OF THE SAME |
| abstract | Refers to a derivative of glucagon or a conjugate containing the same, and specifically, a pharmaceutical composition, comprising a peptide comprising the amino acid sequence of the following general formula 1: X1-X2-QGTF-X7-SD -X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X23-X24-WL-X27-X28-X29-X30 (General Formula 1, SEQ ID NO: 45), where X1 is histidine (H), deamino-histidyl, N-dimethyl-histidyl, beta-hydroxyimidazopropionyl, 4-imidazoacetyl, among others; X2 is alpha-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine (G), among others; X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X13 is tyrosine (Y) or cysteine (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D), glutamic acid (E), or cysteine (C); X16 is glutamic acid (E), aspartic acid (D), serine (S), alpha-methyl-glutamic acid, or cysteine (C), or is absent; X17 is aspartic acid (D), glutamine (Q), glutamic acid (E), among others; X18 is alanine (A), aspartic acid (D), glutamic acid (E), among others; X19 is alanine (A), arginine (R), among others; X20 is lysine (K), histidine (H), among others; X21 is aspartic acid (D), glutamic acid (E); among others; X23 is isoleucine (I), valine (V), among others; X24 is valine (V), arginine (R), among others, X27 is isoleucine (I), valine (V), among others; X28 is glutamine (Q), lysine (K); X29 is lysine (K), alanine (A); X30 is cysteine (C); among others; where the C-terminal end of the peptide is amidated, unmodified and the peptide is a native glucagon derivative capable of activating a glucagon receptor, which comprises an amino acid sequence consisting of SEQ ID NOS: 2 to 44. Also refers to an isolated conjugate comprising a peptide moiety and a moiety of biocompatible material that binds to the rest of the peptide. Said pharmaceutical composition is useful to prevent or treat hypoglycemia, metabolic syndrome and congenital hyperinsulinism. |
| priorityDate | 2016-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.